ArticleJournal of Ayurveda and integrative medicine
Standardization, anti-carcinogenic potential and biosafety of Indian propolis.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- Therapeutic Potential of Propolis in Preclinical Models of Cancer and Infectious Diseases: A Review.International journal of molecular sciences · 2025Review
- Propolis Extract with Activity AgainstAntioxidants (Basel, Switzerland) · 2025Article
- Synthesis, characterisation and in vitro anticancer activity of conjugated protease inhibitor-silver nanoparticles (AgNPs-PI) against human breast MCF-7 and prostate PC-3 cancer cell lines.Bioprocess and biosystems engineering · 2024Article
- Development of propolis, hyaluronic acid, and vitamin K nano-emulsion for the treatment of second-degree burns in albino rats.BMC complementary medicine and therapies · 2024Article
- Formulation Development and Evaluation of Indian Propolis Hydrogel for Wound Healing.Gels (Basel, Switzerland) · 2023Article
- Effect of Hydrogen-Enriched Solvents on the Extraction of Phytochemicals in Propolis.ACS omega · 2023Article
- Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer's Disease.Oxidative medicine and cellular longevity · 2022Review
- Design and characterization of propolis extract loaded self-nano emulsifying drug delivery system as immunostimulant.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- A New Controlled Release System for Propolis Polyphenols and Its Biochemical Activity for Skin Applications.Plants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPropolis from apiculture is known for wide range of medicinal properties owing to its vast chemical constituents including polyphenols, flavonoids and anticancer agent Caffeic acid phenethyl ester (CAPE).
objectivesThe objective of the study was to extract and standardize Indian propolis (IP) with respect to selected markers by newly developed High performance liquid chromatography (HPLC) method, to evaluate in vitro and in vivo anticancer activity and biosafety of Indian propolis. MATERIALS AND
methodsIP was extracted, optimized and standardized using a newly developed and validated HPLC method for simultaneous estimation of caffeic acid, apigenin, quercetin and CAPE. The standardised ethanolic extract of IP (EEIP) was screened for in vitro cytotoxicity using sulforhodamine B (SRB) assay, in vivo anti-carcinogenic effect against Dalton's Lymphoma ascites (DLA) cells, hemolytic effect and pesticide analysis.
resultsThe EEIP was found to contain more amount of total flavonoids (23.61 ± 0.0452 mg equivalent of quercetin/g), total polyphenolics (34.82 ± 0.0785 mg equivalent of gallic acid/g) and all selected markers except caffeic acid compared to all other extracts. EEIP showed better anti-cancer potential than CAPE on MCF-7 and HT-29 cell line and significant (p < 0.01) in vivo anti-carcinogenic effects against DLA in comparison with 5-fluorouracil. EEIP was found to be non-hemolytic.
conclusionFrom in vitro cytotoxicity, in vivo anti-carcinogenicity and biosafety studies it can be concluded that the standardized EEIP is safe and can be considered for further development as a biomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.